Evidence map›Paper›PMID 37256908›Full record

ArticlePLoS pathogens2023

Airway proteolytic control of pneumococcal competence.

Haley Echlin, Amy Iverson, Ugo Sardo, Jason W Rosch

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Transcriptomic analysis ofMicrobial genomics · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Ultrastructural, metabolic and genetic characteristics of determinants facilitating the acquisition of macrolide resistance by Streptococcus pneumoniae.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Haley EchlinDepartment of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Amy IversonDepartment of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Ugo SardoDepartment of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Jason W RoschDepartment of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee, United States of America.ORCID 0000-0002-1798-1760
St. Jude Children's Research Hospital · US

Funding

Predicting the emergence of antibiotic resistance through multi-omics approaches and Immune System-surveillanU01AI124302 · NIAID · BOSTON COLLEGE · PI BENTO, JOSE, COOPER, VAUGHN · 2016 to 2020
$10.2M
Drug resistance enablers and their role in antibiotic treatment failureU19AI158076 · NIAID · BROAD INSTITUTE, INC. · PI VAN OPIJNEN, TIM · 2022 to 2025
$10.0M
Evolvable essentiality in the pan-genome of Streptococcus pneumoniae and its mechanistic and evolutionary consequencesR01AI171038 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Jason W. Rosch, Federico Antonio Rosconi · 2022 to 2026
$3.0M
Consequences of Direct Viral-Bacterial InteractionsR01AI168214 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Jason W. Rosch, Stacey L Schultz-Cherry · 2022 to 2026
$2.5M
Consequences of Direct Viral-Bacterial InteractionsR56AI155614 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI ORTIZ-MARQUEZ, JUAN CESAR FEDERICO, ROSCH, JASON W. · 2021 to 2021
$531k
NIAID NIH HHS R01 AI168214NIAID NIH HHS R01 AI171038NIAID NIH HHS R56 AI155614NIAID NIH HHS U01 AI124302NIAID NIH HHS U19 AI158076
6 · The paper itself

Abstract

Streptococcus pneumoniae is an opportunistic pathogen that colonizes the upper respiratory tract asymptomatically and, upon invasion, can lead to severe diseases including otitis media, sinusitis, meningitis, bacteremia, and pneumonia. One of the first lines of defense against pneumococcal invasive disease is inflammation, including the recruitment of neutrophils to the site of infection. The invasive pneumococcus can be cleared through the action of serine proteases generated by neutrophils. It is less clear how serine proteases impact non-invasive pneumococcal colonization, which is the key first step to invasion and transmission. One significant aspect of pneumococcal biology and adaptation in the respiratory tract is its natural competence, which is triggered by a small peptide CSP. In this study, we investigate if serine proteases are capable of degrading CSP and the impact this has on pneumococcal competence. We found that CSP has several potential sites for trypsin-like serine protease degradation and that there were preferential cleavage sites recognized by the proteases. Digestion of CSP with two different trypsin-like serine proteases dramatically reduced competence in a dose-dependent manner. Incubation of CSP with mouse lung homogenate also reduced recombination frequency of the pneumococcus. These ex vivo experiments suggested that serine proteases in the lower respiratory tract reduce pneumococcal competence. This was subsequently confirmed measuring in vivo recombination frequencies after induction of protease production via poly (I:C) stimulation and via co-infection with influenza A virus, which dramatically lowered recombination events. These data shed light on a new mechanism by which the host can modulate pneumococcal behavior and genetic exchange via direct degradation of the competence signaling peptide.

Indexed as

Pneumococcal InfectionsStreptococcus pneumoniaeAnimalsInflammationMicePeptidesSerine ProteasesPeptidesSerine Proteases

Identifiers

PMID37256908
PMCPMC10259803
OpenAlexW4378904841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.